Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$1,060.86 USD
+5.29 (0.50%)
Updated Jul 24, 2024 04:00 PM ET
Pre-Market: $1,065.30 +4.44 (0.42%) 9:04 AM ET
4-Sell of 5 4
D Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1,060.86 USD
+5.29 (0.50%)
Updated Jul 24, 2024 04:00 PM ET
Pre-Market: $1,065.30 +4.44 (0.42%) 9:04 AM ET
4-Sell of 5 4
D Value D Growth F Momentum F VGM
Zacks News
Regeneron vs. Alexion: Which Stock is a Better Pick Post Q2 Earnings?
by Arpita Dutt
Biotech companies, Regeneron (REGN) and Alexion, both topped estimates in Q2 and raised their outlook. But, which stock is better-positioned for the second half of the year?
Forget Teva (TEVA), Buy These 4 Drug Stocks Instead
by Arpita Dutt
With generic drugmakers like Teva (TEVA) under pressure, here is a look at four drug stocks that look well-positioned.
Puma (PBYI) Q2 Loss Narrower than Expected, Nerlynx in Focus
by Zacks Equity Research
Puma Biotechnology (PBYI) reported narrower-than-expected loss in Q2. Shares were down in after-hours trading.
Geron (GERN) Q2 Loss Narrows, Sales Miss Estimates, Stock Up
by Zacks Equity Research
Geron Corporation (GERN) reported narrower-than-expected loss in Q2 while sales missed estimates. Shares were up in after-hours trading.
Inovio (INO) Q2 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Inovio Pharmaceuticals (INO) reports narrower-than-expected loss with revenue beating estimates. Moreover, the top line significantly increases year over year.
Biotech Stock Roundup: Q2 Earnings from Regeneron, Kite & More, FibroGen Up on IPF Data
by Arpita Dutt
Regeneron (REGN) and several other biotech companies reported Q2 earnings while FibroGen hit a 52-week high on promising idiopathic pulmonary fibrosis (IPF) data.
The Zacks Analyst Blog Highlights: ExxonMobil, MasterCard, Shell, Regeneron and BP
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ExxonMobil, MasterCard, Shell, Regeneron and BP
Top Research Reports for ExxonMobil, MasterCard & Shell
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including ExxonMobil (XOM), MasterCard (MA), and Shell (RDS.A).
Regeneron (REGN) Beats on Q2 Earnings & Sales, Raises View
by Zacks Equity Research
Regeneron Pharmaceuticals, Inc. (REGN) reported strong second-quarter results wherein both earnings and sales beat expectations on the back of Eylea sales.
Regeneron (REGN) Q2 Earnings Beat Estimates
by Ekta Bagri
Regeneron Pharmaceuticals (REGN) reported second quarter results, beating estimates on both counts
What's in the Cards for Adverum (ADVM) this Earnings Season?
by Zacks Equity Research
Investors will be looking at Adverum's (ADVM) updates on progress of its various pipeline candidates.
Sanofi (SNY) Q2 Earnings In Line, Sales Lag,'17 View Raised
by Zacks Equity Research
Sanofi (SNY) Q2 results were mixed as it reported in-line earnings and slightly missed sales expectations. However, the company raised its 2017 earnings guidance.
Ophthotech (OPHT) Q2 Loss Narrows, Focus Shifts to Zimura
by Zacks Equity Research
Ophthotech Corporation (OPHT) reported narrower-than-expected loss in the second quarter and also beat sales expectations.
Can Regeneron Pharma (REGN) Pull a Surprise in Q2 Earnings?
by Zacks Equity Research
Regeneron Pharmaceuticals, Inc. (REGN) is scheduled to release second-quarter 2017 results on Aug 3 and we expect focus on Eylea's performance.
5 Top Multibagger Biotech Stocks to Buy in the 2nd Half
by Tirthankar Chakraborty
Draconian crackdown on drug prices easing out and likelihood of a series of buyouts will help innovation starved biotech companies to gain in the second half.
Sanofi Versus AstraZeneca: Large Cap Pharma Stock Faceoff
by Zacks Equity Research
Both stocks carry a Zacks Rank #2 (Buy).
Apple's Tim Cook earns $145M in 2016, Tops S&P 500 CEOs
by Zacks Equity Research
Apple Inc.'s (AAPL) Chief Executive Officer (CEO) Tim Cook has been declared the highest-paid CEO in the U.S., per a Bloomberg's report of take-home pay for the top 25 S&P 500 CEOs.
BioMarin Files BLA for Phenylketonuria Candidate Pegvaliase
by Zacks Equity Research
BioMarin Pharmaceutical Inc. (BMRN) announced that it has filed a biologics license application (BLA) with the FDA for its pipeline candidate, pegvaliase for phenylketonuria (PKU).
Roche (RHHBY) Launches Cobas Test for Bacterial Infections
by Zacks Equity Research
Roche Holdings AG (RHHBY) launched CE-IVD, the cobas MRSA/SA nucleic acid test be used on the cobas Liat System for the qualitative detection and differentiation of methicillin-resistant MRSA and SA at the point of care.
Marinus' (MRNS) Ganaxolone Gets Orphan Drug Status in US
by Zacks Equity Research
Marinus Pharmaceuticals, Inc. (MRNS) announced that the FDA has granted orphan drug designation to its key candidate, ganaxolone, for the treatment of adult and pediatric patients with CDKL5 disorder.
Amgen's Colorectal Cancer Drug Gets FDA Nod to Expand Label
by Zacks Equity Research
Amgen, Inc. (AMGN) announced that the FDA has approved a label expansion of its colorectal cancer drug, Vectibix.
Acorda Files NDA for Parkinson's Disease Candidate Inbrija
by Zacks Equity Research
Acorda Therapeutics, Inc. (ACOR) has submitted a new drug application to FDA for its late stage pipeline candidate Inbrija for treatment of patients suffering from Parkinson's disease.
Zacks.com featured highlights: Principal Financial Group, Regeneron Pharmaceuticals, Zebra Technologies, United Technologies and T. Rowe Price Group
by Zacks Equity Research
Zacks.com featured highlights: Principal Financial Group, Regeneron Pharmaceuticals, Zebra Technologies, United Technologies and T. Rowe Price Group
Sarepta Appoints Ex-Allergan Executive as CEO and President
by Zacks Equity Research
Sarepta Therapeutics, Inc. (SRPT) announced the appointment of Douglas S. Ingram as the new chief executive officer (CEO).
Robust 1H for Pharma/Biotech Sector, 3 Big Stocks to Buy
by Zacks Equity Research
The pharma and biotech industry has been blessed with good health in the first half of the year.